Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin for NAAT(+)/Toxin EIA(-) Clostridium Difficile
NCT03827447Phase 1Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing Vancomycin Group with Placebo Group (2 arms). Primary endpoints: Change in C. difficile loads at Day 28 and Long-term persistence of C. difficile from the change in qPCR levels at Day 90. Started Jul 2019; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03827447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827447.